Log in
  Subscribe
  • Home
  • 2016 LLA Award Winner - Mentor Me

2016 Leading Light Award Winner - Mentor Me!

Linda Rorick-KehnLinda Rorick-Kehn, Principal Research Scientist, Lilly Research Labs, a division of Eli Lilly and Company

Linda is a Principal Research Scientist in the Neurophysiology group at Lilly Research Labs, a division of Eli Lilly and Company, where she assembles and leads teams made up of diverse, interdisciplinary scientists.

Linda has shown that she is dedicated to the development of female talent at Lilly since joining Lilly’s team as a post-doctoral scientist. She has mentored other post-doctoral scientists, and associate and senior level scientists; supervised consultant scientists and helped others advance in their professional development. She is currently the co-leader of the Women in Lilly Discovery and Development (WILDD) group.

Linda has not only influenced her fellow scientists at Lilly, she has also had a profound impact on young women pursuing degrees in STEM. Recently, she created and executed a one-of-a-kind outreach program with Indiana University for students interested in pursuing STEM-related careers. The program focused on giving college students insight into research in the pharmaceutical industry, and was attended by undergraduate students in the Women in STIM program; graduate students in Chemistry, Biology, and Neuroscience programs; and students in the IU Kelley School of Business Entrepreneurship Program.

Linda’s influence on women in STEM spans from young students to senior-level scientists. She has demonstrated leadership and remarkable mentoring skills, and creates incredible connections amongst peers and mentees, built on empathy, trust and respect.

Patents:
1. Method of use patent: Rorick-Kehn LM (WO 2013/085781A). ORL-1 receptor antagonists for the treatment of alcohol dependence and abuse. US provisional application 61/567,242; published 13-June-2013.

Publications:
25. Witkin JM, Rorick-Kehn LM, Benvenga MJ, Adams BL, Gleason SD, Knitowski KM, Li X, Chaney S, Falcone JF, Smith J, Foss J, Lloyd K, Catlow JT, McKinzie DL, Svensson KA, Barth VN, Toledo MA,  Diaz N, Lafuente C, Jimenez A, Benito A, Pedregal C, Martinez-Grau MA, Post A, Ansonoff MA, Pintar  JE, Statnick MA (under review) LY29400094, the first antagonist of nociceptin receptors with a positive  
signal in patients with major depressive disorder: Preclinical findings predicting efficacy and side-effect profile. J Pharmacol Exp Ther  

24. Post A, Smart TS, Jackson K, Wilson J, Mohs R, Rorick-Kehn LM, Statnick MA, Anton R, O’Malley S, Wong CJ (in press) A proof-of- concept trial to assess the nociceptin receptor antagonist LY2940094 as a new treatment for alcohol dependence. Alcohol Clin Exp Res  
23. Scuppa G, Kallupi M, de Guglielmo G, Calò G, Weiss F, Statnick MA, Rorick-Kehn LM, Ciccocioppo R (in press) Genetic deletion of the nociceptin/orphanin FQ receptor in the rat confers resilience to the  development of drug addiction.  Neuropsychopharmacol  

22. Witkin JM, Monn JA, Schoepp DD, Li X, Overshiner C, Mitchell SN, Carter G, Johnson B, Rasmussen K and Rorick-Kehn LM (2016) The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits. J Pharmacol Exp Ther 358:71-82.  

21. Rorick-Kehn LM, Ciccocioppo R, Wong CJ, Witkin JM, Martinez-Grau MA, Stopponi S, Adams BL, Katner JS, Perry KW, Toledo MA, Diaz N, Lafuente C, Jimenez A, Benito A, Pedregal C, Weiss F and Statnick MA (2016) A novel, orally bioavailable nociceptin receptor antagonist, LY2940094, reduces ethanol self-administration and ethanol seeking in animal models. Alcohol Clin Exp Res 40: 945-954.
 
20. Statnick MA, Chen Y, Ansonoff M, Witkin JM, Rorick-Kehn LM, Suter TM, Song M, Hu C, Lafuente C, Jiménez A, Benito A, Diaz N, Martínez-Grau MA, Toledo MA, Pintar JE. (2016) A novel nociceptin  receptor antagonist LY2940094 inhibits excessive feeding behavior in rodents: A possible mechanism for the treatment of binge eating disorder. J Pharmacol Exp Ther 356: 493-502.  

19. Rorick-Kehn LM, Witcher J, Weller MA, Bell RL, Wong CJ, Gonzales C, Hart JC, McKinzie JH, Statnick MA, Need A, Suico JG, McKinzie DL, Tauscher-Wisniewski S, Mitch CH, Lowe SL (2015)   Determining Pharmacological Selectivity of the Kappa Opioid Receptor Antagonist LY2456302 using  Pupillometry as a Translational Biomarker in Rat and Human. Int J Neuropsychopharmacol, 18.  

18. Lowe SL, Wong CJ, Witcher J, Gonzales CR, Dickinson GL, Bell RL, Rorick-Kehn LM, Weller M, Stoltz RR, Royalty J, Tauscher-Wisniewski S (2014). Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects. J Clin Pharmacol 54: 968-978.  

17. Anderson RI, Becker HC, Adams BL, Jesudason CD and Rorick-Kehn LM (2014) Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models. Front Neurosci  8:33.  

16. Fitch TE, Benvenga MJ, Jesudason CD, Zink C, Vandergriff AB, Menezes MM, Schober DA and Rorick-Kehn LM (2014) LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin- 1 receptors and activity in an animal model predictive of antidepressant-like efficacy. Front Neurosci 8:5.  

15. Witkin JM, Statnick MA, Rorick-Kehn LM, Pintar JE, Ansonoff M, Chen Y, Tucker RC and Ciccocioppo R (2014) The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence. Pharmacol Ther 141:283-299.
 
14. Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, Forster BM, Wong CJ, Li X, Crile RS, Shaw DB, Sahr AE, Adams BL, Quimby SJ, Diaz N, Jimenez A, Pedregal C, Mitch CH, Knopp KL, Anderson WH, Cramer JW and McKinzie DL (2014) LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of  
efficacy in mood and addictive disorders. Neuropharmacology 77:131-144.

13. Watt ML, Rorick-Kehn L, Shaw DB, Knitowski KM, Quets AT, Chesterfield AK, McKinzie DL and Felder CC (2013) The muscarinic acetylcholine receptor agonist BuTAC mediates antipsychotic-like effects via the M4 subtype. Neuropsychopharmacology 38:2717-2726.  

12. Melief EJ, Miyatake M, Carroll FI, Beguin C, Carlezon WA, Jr., Cohen BM, Grimwood S, Mitch CH, Rorick-Kehn L and Chavkin C (2011) Duration of Action of a Broad Range of Selective {kappa}-Opioid Receptor Antagonists Is Positively Correlated with c-Jun N-Terminal Kinase-1 Activation. Mol  Pharmacol 80:920-929.
 
11. Fell MJ, Witkin JM, Falcone JF, Katner JS, Perry KW, Hart J, Rorick-Kehn L, Overshiner CD, Rasmussen K, Chaney SF, Benvenga MJ, Li X, Marlow DL, Thompson LK, Luecke SK, Wafford KA, Seidel WF, Edgar DM, Quets AT, Felder CC, Wang X, Heinz BA, Nikolayev A, Kuo MS, Mayhugh D, Khilevich A, Zhang D, Ebert PJ, Eckstein JA, Ackermann BL, Swanson SP, Catlow JT, Dean RA, Jackson K, Tauscher-Wisniewski S, Marek GJ, Schkeryantz JM and Svensson KA (2011) N-(4- ((2-(trifluoromethyl)-  3-hydroxy- 4-(isobutyryl)phenoxy)methyl)benzyl)- 1-methy l-1H- imidazole-4- carboxamide (THIIC), a  novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo   profiling suggests a link between behavioral and central nervous system neurochemical changes. J Pharmacol Exp Ther 336:165-177.  

10. Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, Griffey KI, Tizzano JP, Monn JA, McKinzie DL and Schoepp DD (2007) In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl) 193:121-136.  

9. Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, Nisenbaum ES, Catlow JT, Kingston AE, Giera DD, Herin MF, Monn JA, McKinzie DL and Schoepp DD (2007) Pharmacological and Pharmacokinetic Properties of a Structurally Novel, Potent, and Selective Metabotropic Glutamate 2/3 Receptor Agonist: In Vitro Characterization of Agonist (-)- (1R,4S,5S,6S)-4- Amino-2-  
sulfonylbicyclo[3.1.0]-hexane- 4,6-dicarboxylic Acid (LY404039). J Pharmacol Exp Ther 321:308-317.

8. Smith DG, Davis RJ, Rorick-Kehn L, Morin M, Witkin JM, McKinzie DL, Nomikos GG and Gehlert DR 2006) Melanin-concentrating hormone-1 receptor modulates neuroendocrine, behavioral, and corticolimbic neurochemical stress responses in mice. Neuropsychopharmacology 31:1135-1145.  

7. Rorick-Kehn LM, Perkins EJ, Knitowski KM, Hart JC, Johnson BG, Schoepp DD and McKinzie DL (2006) Improved Bioavailability of the mGlu2/3 Receptor Agonist LY354740 Using a Prodrug Strategy: In Vivo Pharmacology of LY544344. J Pharmacol Exp Ther 316:905-913.
 
6. Rorick-Kehn LM and Steinmetz JE (2005) Amygdalar unit activity during three learning tasks: Eyeblink classical conditioning, Pavlovian fear conditioning, and signaled avoidance conditioning. Behav Neurosci  119:1254-1276.
 
5. Rorick-Kehn LM, Hart JC and McKinzie DL (2005) Pharmacological characterization of stress-induced hyperthermia in DBA/2 mice using metabotropic and ionotropic glutamate receptor ligands.  Psychopharmacology (Berl) 183:226-240.  

4. Rorick LM, Finn PR and Steinmetz JE (2004) Heart rate reactivity in HAD and LAD rats during Pavlovian fear conditioning. Integr Physiol Behav Sci 39:24-41.  

3. Rorick LM, Finn PR and Steinmetz JE (2003) High-alcohol- drinking rats exhibit persistent freezing responses to discrete cues following Pavlovian fear conditioning. Pharmacol Biochem Behav 76:223-230.  

2. Rorick LM, Finn PR and Steinmetz JE (2003) Moderate doses of ethanol partially reverse avoidance learning deficits in High-Alcohol- Drinking rats. Pharmacol Biochem Behav 75:89-102.  

1. Finn PR, Justus AN, Mazas C, Rorick L and Steinmetz JE (2001) Constraint, alcoholism, and electrodermal response in aversive classical conditioning and mismatch novelty paradigms. Integr Physiol Behav Sci 36:154-167.
 
Oral Presentations and Invited Talks:
26. Gehlert DR, Paterson B, Jackson A, Damaj I, Rorick-Kehn L (2016). The effects of CERC-501, a potent and selective kappa opioid receptor antagonist on morphine withdrawal in mice. Presented at the annual  meeting of the College on Problems of Drug Dependence, Palm Springs, CA, June 2016.  

25. Gehlert DR, Rorick-Kehn L, Thorsell A, Paterson B, Heilig M (2016). Evaluation of CERC-501, a selective kappa opioid antagonist in preclinical models of alcoholism. Presented at the annual meeting of the College on Problems of Drug Dependence, Palm Springs, CA, June 2016.  

24. Rorick-Kehn LM (2015) Neuroscience drug discovery: Current research and illuminating potential breakthroughs. Presented at Indiana University Program in Neuroscience, Bloomington, IN, September  2015.  

23. Martinez-Grau MA, Pedregal C, Toledo MA, Diaz N, Lafuente C, Jimenez A, Benito AB, Witkin JM, Statnick MA, McKinzie DL, Rorick-Kehn LM, Barth VN, Kahl SD, Mudra DR. (2015) Property-based optimization of NOP receptor antagonists based on a potent thienospiro-piperidine scaffold. Presented at  the semiannual meeting of the American Chemical Society, Boston MA, August 2015.  

22. Rorick-Kehn LM, Johnson BG, Knitowski KM, Need AB, Kahl SD, Statnick MA, McKinzie JH, Crile RS, Li X, Witkin JM, Diaz Buezo N, Quimby SJ, Mitch CH, Rasmussen K, McKinzie DL. (2015) The novel, potent, short-acting kappa opioid receptor antagonist, LY2444296, modulates mesoaccumbens  dopamine neurotransmission and dopamine-mediated behaviors. Presented at the biennial meeting of the Kappa Therapeutics Conference, Chapel Hill, NC, April 2015.
 
21. Rorick-Kehn LM, Ciccocioppo R, Adams BL, Katner JS, Perry KW, Witkin JM, Toledo MA, Diaz N, Lafuente C, Jiménez A, Benito1 A, Martínez-Grau MA, Pedregal C, Statnick MA. (2014) A novel,  potent, orally-bioavailable nociceptin-1 receptor antagonist reduces ethanol self-administration and  ethanol-seeking in animal models of alcohol addiction. Presented at the annual meeting of the Behavioral  Pharmacology Society, San Diego, CA, April 2014.   

20. Witkin JM, Statnick M, Rorick-Kehn L, Barth V, Wafford K, Pintar J, Perry K, Toledo MA, Diaz N, Lafuente C, Jiménez A, Benito A, Martínez-Grau MA, Pedregal C. (2014) A novel nociceptin-1 receptor  antagonist produces novel antidepressant- and anxiolytic-related effects in rodents. Presented at the annual meeting of the Behavioral Pharmacology Society, San Diego, CA, April 2014.  

19. Rorick-Kehn LM (2014). Preclinical and clinical translational biomarker and PET studies on the kappa opioid receptor antagonist, LY2456302, for the treatment of mood and addictive disorders. Presented as  part of the MUSC Addiction Research Seminar Series, Charleston, SC, March 2014.  

18. Feagans AC, Morin SM, Thompson LK, Knitowski KM, Gehlert DR, McKinzie DL, Rorick-Kehn LM (2014). Alterations in orexin neuropeptide levels may contribute to neuroadaptive changes that lead to addiction. Presented at the Indiana Physiological Society, Evansville, IN, February 2014.  

17. Rorick-Kehn LM, Witcher JW, Bell RL, Wong CJ, Gonzales CR, Hart JC, McKinzie JH, Statnick MA, Need AB, Suico JD, McKinzie DL, Tauscher JT, Mitch CH, Lowe SL (2013). The translation of rat to human pupillometry studies to determine the functional selectivity of the kappa opioid receptor antagonist LY2456302. Presented at the biennial meeting of the Kappa Therapeutics Conference, Boston, MA, April 2013.  

16. Rorick-Kehn L, Crile R, Sahr A, McKinzie J, Statnick M, Need A, Adams B, Li X, Witkin J, Shaw D, Kahl S, Quimby S, Diaz N, Mitch C, Jimenez A, Pedregal C, McKinzie D (2012) Preclinical pharmacological characterization of structurally-unique, potent, kappa opioid receptor antagonists in animal models of alcohol dependence and mood disorders. Presented at the Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY, August 2012.  

15. Rorick-Kehn L, Crile R, Sahr A, McKinzie J, Statnick M, Need A, Adams B, Li X, Witkin J, Shaw D, Kahl S, Quimby S, Diaz N, Mitch C, Jimenez A, Pedregal C, McKinzie D (2012) Preclinical pharmacological characterization of structurally-unique, potent, kappa opioid receptor antagonists in animal models of alcohol dependence and mood disorders. Presented at the annual meeting of the College on Problems of Drug Dependence, Palm Springs, CA, June 2012.  

14. Rorick-Kehn L, Crile R, Sahr A, McKinzie J, Statnick M, Need A, Adams B, Li X, Witkin J, Shaw D, Kahl S, Quimby S, Diaz N, Mitch C, Jimenez A, Pedregal C, McKinzie D (2012) Preclinical pharmacological characterization of structurally-unique, potent, kappa opioid receptor antagonists in animal models of alcohol dependence and mood disorders. Presented at the annual NCDEU meeting (New Clinical Drug Evaluation Unit, sponsored by the American Society of Clinical Psychopharmacology), Phoenix, AZ, May 2012.

13. Melief EJ, Miyatake M, Carroll FI, Beguin C, Carlezon WA, Cohen BM, Grimwood S, Mitch CH, Rorick- Kehn L, Chavkin C (2011) Duration of action of a broad range of selective kappa opioid receptor antagonists is positively correlated with c-Jun N-terminal Kinase-1 activation. Presented at the Therapeutic Potential of Kappa Opioids in Pain and Addiction Conference, Seattle, WA, July 2011.
 
12. Rorick-Kehn L, Crile R, Sahr A, McKinzie J, Statnick M, Need A, Adams B, Li X, Witkin J, Shaw D, Kahl S, Quimby S, Diaz N, Mitch C, Jimenez A, Pedregal C, McKinzie D (2011) Preclinical pharmacological characterization of structurally-unique, potent, kappa opioid receptor antagonists, FP3FBZ and LY2456302, in animal models of alcohol dependence and mood disorders. Presented at the Therapeutic Potential of Kappa Opioids in Pain and Addiction Conference, Seattle, WA, July 2011.  

11. McKinzie DL, Crile RS, Knitowski KM, Shaw DB, Rorick-Kehn LM, Hart JC, Marek GJ, Wright RA, Witkin JM, Li X, Shannon HE, Trowbridge MA, Kingston AE, Day TA, Johnson KW, Dieckman DK, Iyengar S, Simmons RM, White R, Dressman B, Monn JA (2008) Metabotropic glutamate receptor-5 antagonists for the treatment of drug dependence and beyond: Characterization of the novel mGlu5 receptor antagonist LY2300979. Presented at the International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, October 2008.  

10. Rorick-Kehn L, Adams B, Hart J, Crile R, McKinzie D, Menezes M, Marek G, Merchant K, Morin M, Gehlert D (2007) Orexin (hypocretin) receptor antagonists as potential therapeutic targets for the treatment of anxiety and addictive disorders. Presented at the annual meeting of the Research Society on Alcoholism, Chicago, IL, July 2007.  

9. McKinzie DL, Rorick-Kehn LM, Schoepp DD, Rodd Z, McBride W (2006) Metabotropic glutamate receptors as potential targets for the treatment of alcoholism. Presented at the annual meeting of the Research Society on Alcoholism, Baltimore, MD, June 2006.
 
8. Rorick-Kehn LM, McKinzie DL (2006) The role of metabotropic glutamate receptors in substance abuse. Presented at the annual meeting of the American Society for Pharmacology and Experimental Therapeutics, San Francisco, CA, April 2006.  

7. Felder CC, Nomikos GG, Rorick-Kehn LM, Wess J, McKinzie DL (2005) Understanding the physiological function of the 5 muscarinic receptor subtypes and their potential role as targets in the treatment of psychosis. Presented at the annual joint meeting of the Collegium Internationale Neuro-Psychopharmacologicum and the Australian Society for Psychiatric Research, Brisbane, Australia,  
December 2005.

6. McKinzie DL, Rorick-Kehn LM, Schoepp DD, Rodd Z, McBride W (2005) Metabotropic glutamate ligands for the treatment of addiction disorders. Presented at the 5 th International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, September 2005.
 
5. Rorick-Kehn LM, McKinzie DL (2005) Development of animal models for testing novel treatments for alcoholism. Presented at Lilly Research Laboratories, Indianapolis, IN, July 2005.
 
4. Rorick-Kehn LM, Crile RS, Peters SC, Shannon HE, McKinzie DL (2005) Schedule-induced ethanol self-administration in C57BL/6J mice: Disruption of ethanol drinking by several different neuro-pharmacological mechanisms. Presented at the annual meeting of the Research Society on Alcoholism, Santa Barbara, CA, June 2005.  

3. Rorick LM, Steinmetz JE (2003). Amygdala unit activity during three aversive learning tasks: Eyeblink classical conditioning, Pavlovian fear conditioning, and signaled avoidance conditioning.   Presented at the Department of Psychology, Indiana University, Bloomington, IN, February 2003.  

2. Rorick LM, Steinmetz JE (2000) Classical fear conditioning as an index of anxiety in High-Alcohol- Drinking (HAD) rats. Presented at the 13 th annual Tri-State Conference on Animal Learning and Behavior, West  Lafayette, IN, February 2000.  

1. Finn PR, Rorick LM, Steinmetz JE (1997) Biobehavioral mediators of early-onset, antisocial alcohol abuse in men and women: Response to threat and passive avoidance learning. Invited talk  presented at a symposium on Psychophysiological Studies of Biobehavioral Mediators of Risk for  Alcohol Abuse. Presented at the annual meeting of the Society for Psychophysiological Research, North Falmouth, MA, November 1997.  

Posters Presented:
  • Choong CK, Rorick-Kehn LM, Wall TM, Muhlhauser M, Krajewski J, Chi XX, Fitch T, Forster B, Simmons RA, Wilenkin B, Krambis MJ, Raub T, Knopp K, Blanco M, Shi Q, Johnston R, McDermott J, Priest B, Rasmussen K, Nisenbaum E (2015) An in vivo electrophysiological assay to assess blood-nerve barrier penetration in the sciatic nerve. Presented at the annual meeting of the Society for Neuroscience, Chicago, IL, October 2015.  
  • Rasmussen K, Witkin JM, Rorick-Kehn L (2014). Ketamine and the mGlu2/3 receptor antagonist LY341495 rapidly engage dopaminergic mood circuits to engender antidepressant-related behavioral effects.  Presented at the 53rd annual meeting of the American College of Neuropsychopharmacology, Phoenix, AZ, December 2014.  
  • Witkin JM, Overshiner C, Li X, Gilmour G, Li J, Wafford K, Rorick-Kehn L, Rasmussen K, Johnson B, Mitchell SN, McKinzie DL, Nikolayev A, Tolstikov VV, Kuo M-S, Ornstein PL, Mitch CH, Li R, Smith SC, Wang X-S, Heinz BA, Allen D, Swanson S, Monn JA (2014) LY3020371: In vivo characterization of a novel mGlu2/3 receptor antagonist. Presented at the 8th International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, October 2014.
  • McKinzie D, Johnson B, Knitowski K, Shaw D, Rorick-Kehn L, Katner J, Perry K, Swanson S, Catlow J, Johnson M, Prieto L, Beadle C, Monn J. LY2969822: Pharmacological characterization of an orally bioavailable prodrug for a potent, selective mGlu2/3 receptor agonist. Presented at the triennial meeting of the International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, October 2014.
  • McKinzie D, Heinz B, Wang X, Schober D, Felder C, Sanger H, Vivier R, Siuda E, Nisenbaum E, Thompson L, Johnson B, Knitowski K, Shaw D, Rorick-Kehn L, Katner J, Perry K, Johnson M, Wang C, Beadle C, Atwell S, Lu F, Clawson D, Bures M, Swanson S, Monn J. LY2934747: In Vitro and In Vivo Characterization of a Novel mGlu2/3 Receptor Agonist. Presented at the triennial meeting of the International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, October 2014.
  • Rorick-Kehn LM, Witcher JW, Lowe SL, CR Gonzales, Bell RL, Hart JC, McKinzie JH, Statnick MA, Need AB, Suico JG, McKinzie DL, Tauscher-Wisniewski S, Mitch CH, Stoltz RR, Wong CJ. Determining pharmacological selectivity of the kappa opioid receptor antagonist LY2456302 using translational rat to human pupillometry studies. Presented at the annual meeting of the American Society of Clinical Psychopharmacology (formerly NCDEU), Hollywood, FL, June 2014.
  • Rorick-Kehn LM, Ciccocioppo R, Adams BL, Katner JS, Perry KW, Witkin JM, Toledo MA, Diaz N, Lafuente C, Jiménez A, Benito1 A, Martínez-Grau MA, Pedregal C, Statnick MA. (2014) A novel, potent, orally-bioavailable nociceptin-1 receptor antagonist reduces ethanol self-administration and ethanol-seeking in animal models of alcohol addiction. Presented at the annual meeting of the American Society for Pharmacology and Experimental Therapeutics, San Diego, CA, April 2014.
  • Witkin JM, Statnick M, Rorick-Kehn L, Barth V, Wafford K, Pintar J, Perry K, Toledo MA, Diaz N, Lafuente C, Jiménez A, Benito A, Martínez-Grau MA, Pedregal C. (2014) A novel nociceptin-1 receptor antagonist produces novel antidepressant- and anxiolytic-related effects in rodents. Presented at the annual meeting of the American Society for Pharmacology and Experimental Therapeutics, San Diego, CA, April 2014.
  • Rasmussen K, Witkin JM, Rorick-Kehn L (2014). Ketamine and the mGlu2/3 receptor antagonist LY341495 rapidly engage dopaminergic mood circuits to engender antidepressant-related behavioral effects. Presented at the annual meeting of the Society of Biological Psychiatry, New York, NY, May 2014.
  • Feagans AC, Morin SM, Thompson LK, Knitowski KM, Gehlert DR, McKinzie DL, Rorick-Kehn LM (2014). Alterations in orexin neuropeptide levels may contribute to neuroadaptive changes that lead to addiction. Presented at the Indiana Physiological Society, Evansville, IN, February 2014.
  • Khilevich A, Mayhugh DR, Hay DA, Svensson KA, Falcone JF, Heinz BA, Wang X, Witkin JM, Li X, Hart JC, Rorick-Kehn LM, Benvenga MJ, Chaney SF, Catlow JT, Swanson S, Luecke SH, Marlow DL, Schkeryantz JM (2013) Discovery of LY2607540: A Novel mGluR2 Potentiator for the Treatment of Anxiety and Depression. Presented at the annual meeting of the American Chemical Society, Indianapolis, IN, Sep 2013.
  • Mayhugh DR, Khilevich A, Knobelsdorf JA, Hay DA, Svensson KA, Falcone JF, Swanson , Catlow JT, Rorick- Kehn L, Hart JC, Heinz B, Wang X, Benvenga MJ, Chaney S, Li X, Schkeryantz JM (2013). Discovery of LSN2535717, a Selective, Orally Active mGluR2 Positive Allosteric Modulator (PAM): Lead Generation SAR and Effects in Animal Models of Anxiety. Presented at the annual meeting of the American Chemical Society, Indianapolis, IN, Sep 2013.
  • Feagans AC, Morin SM, Thompson LK, Knitowski KM, Gehlert DR, McKinzie DL, Rorick-Kehn LM (2013). Alterations in orexin neuropeptide levels may contribute to neuroadaptive changes that lead to addiction. Presented at the Project SEED meeting sponsored by the American Chemical Society, Indianapolis, IN, July 2013.
  • Witkin JM, Statnick M, McKinzie DL, Rorick-Kehn L, Barth V, Pintar J, Perry K, Toledo MA, Diaz N, Lafuente C, Jiménez A, Benito A, Martínez-Grau M, Pedregal C. (2012) A novel nociceptin-1 receptor antagonist produces antidepressant-, anxiolytic-, and anti-ethanol- associated effects in rodent models. Presented at the annual meeting of the American College of Neuropsychopharmacology, Hollywood, FL, December 2012.
  • O’Neill MJ, Murray TK, Crile RS, Shaw DB, Knitowski KM, Kingston AE, Li X, Day TA, Barth VN, Love P, Teepool A, Wang Y, Wright RA, Phillips KG, Wafford KA, Edgar DM, Seidel W, Walter MW, White R, Dressman BA, Rorick-Kehn L, Witkin JM, Monn JA, McKinzie DL (2012) The in vivo profile of a novel mGlu5 receptor antagonist, LY2300979, indicates activity in animal models of anxiety, alcohol consumption, depression, sleep and Parkinson’s disease. Presented at the annual meeting of the Society for Neuroscience, New Orleans, LA, October 2012.
  • McKinzie D, Monn J, Johnson B, Witkin J, Knitowski K, Shaw D, Rorick-Kehn L, Katner J, Perry K, Li X, Overshiner C, Walton L, Man T, Rudyk H, Clark B, Beadle C, Tupper D, Baker S, Hao J, Reinhard M, Henry S, Massey S, Taboada L, Lamas C, Dominguez C, Montero C, Marcos A, Blanco J, Atwell S, Thompson D, Emtage S, Lu F, Swanson S, Bedwell D, Pak A, Prieto L (2012) In vivo characterization of LY2979165.HCl: A novel, functionally selective orthosteric agonist for the metabotropic glutamate-2 receptor. Presented at the annual meeting of the Society for Neuroscience, New Orleans, LA, October 2012.
  • Adams BL, Gackenheimer SL, Gehlert DR, Statnick MA, Rorick-Kehn LM (2009) Preclinical evaluation of small-molecule nociceptin agonists, Ro 64-6198 and W212393, as potential pharmacotherapies for addictive and anxiety disorders. Presented at the annual meeting of the European Behavioural Pharmacology Society, Rome, Italy.
  • Felder CC, Shaw DB, Chesterfield AK, Knitowski KM, Rorick-Kehn L, McKinzie DL (2008) Preclinical evidence for a role for M4 muscarinic receptors in the pharmacological action of xanomeline. Presented at the annual meeting of the American College of Neuropsychopharmacology, Scottsdale, AZ.
  • Adams B, Menezes M, Crile R, Hart J, Morin M, Falcone J, Svensson K, Gehlert D, Merchant K, McKinzie D, Marek G, Rorick-Kehn L (2007) The effects of orexin-1 receptor blockade on anxiety-like and alcohol- related behavior. Annual meeting of the Society for Neuroscience, San Diego, CA.
  • Rorick-Kehn LM, McKinzie DL (2006) Metabotropic glutamate 5 (mGlu5) receptors may represent viable therapeutic targets for the treatment of alcoholism. Annual meeting of the Research Society on Alcoholism, Baltimore, MD.
  • Smith DG, Davis RJ, Rorick-Kehn LM, Witkin JM, McKinzie DL, Nomikos G, Gehlert DR (2005) Melanin-concentrating hormone-1 receptor modulates neuroendocrine, behavioral and prefrontal cortex neurochemical stress responses. Annual meeting of the North American Association for the Study of Obesity, Vancouver, British Columbia.
  • Rorick-Kehn LM, McKinzie DL (2005) Metabotropic glutamate 5 (mGlu5) receptors may represent viable therapeutic targets for the treatment of alcoholism. Biennial LRL Postdoctoral Research Forum, Lilly Corporate Center, Indianapolis, IN.
  • Smith DG, Davis RJ, Rorick-Kehn LM, Witkin JM, McKinzie DL, Nomikos G, Gehlert DR (2005) Melanin-concentrating hormone-1 receptor modulates neuroendocrine, behavioral and corticolimbic neurochemical stress responses in mice. 15 th annual meeting of the Summer Neuropeptide Conference, Miami, FL.
  • Rorick-Kehn LM, Crile RS, Peters SC, Shannon HE, McKinzie DL (2005) Schedule-induced ethanol self- administration in C57BL/6J mice: Disruption of ethanol drinking by several different neuropharmacological mechanisms. Annual meeting of the Research Society on Alcoholism, Santa Barbara, CA.
  • Rorick LM, Hart JC, McKinzie DL (2004) Mediation of stress-induced hyperthermia in the mouse by ionotropic glutamate receptor ligands. Annual meeting of the International Behavioral Neuroscience Society, Key West, FL.
  • Rorick LM, Steinmetz JE (2003) Neurophysiological characterization of amygdala contributions to eyeblink classical conditioning in rats. Annual meeting of the Pavlovian Society, Bloomington, IN.
  • Rorick LM, Finn PR Steinmetz JE (2002) Multiple measures of classical fear conditioning in High-Alcohol- Drinking (HAD) and Low-Alcohol- Drinking (LAD) rats. Society for Neuroscience Abstracts: Program No. 899.10.
  • Rorick LM, Finn PR, Steinmetz JE (2001) Autonomic and behavioral indices of fear in High-Alcohol- Drinking (HAD) rats during a classical fear conditioning task. Society for Neuroscience Abstracts 27: Program No. 853.19.
  • Rorick LM, Rathburn MK, Finn PR, Steinmetz JE (2000) Classical fear conditioning as an index of anxiety in High-Alcohol- Drinking (HAD1) rats. Society for Neuroscience Abstracts 26: 1817.  
  • Rorick LM, Finn PR, Steinmetz JE (1999) Ethanol reverses deficits in active avoidance learning of high-alcohol-drinking (HAD) rats in signaled bar pressing tasks. Society for Neuroscience Abstracts 25: 1078.
  • Green JT, Rogers RF, Rorick LM, Goodlett CR, Steinmetz JE (1999) Early exposure to alcohol disrupts adult cerebellar-dependent learning. Society for Neuroscience Abstracts 25: 94.
  • Rorick LM, Finn PR, Steinmetz JE (1999) The effects of ethanol on signaled bar pressing tasks in HAD and LAD strains of rats. Alcoholism: Clinical and Experimental Research 23: 105A.
  • Rorick LM (1999) The use of animals in biomedical research: Applications in the study of alcoholism. Women in Science Research Day, Indiana University, Bloomington, IN.  
Awards, Honors, and Affiliations:  
  • Review Editor, Editorial Board, Frontiers in Psychopharmacology, 2016 - present
  • Member, International Association for the Study of Pain, 2016 - present  
  • Early Career Alumni Award, Indiana University Program in Neural Science, September 2015  
  • Member, American Society for Pharmacology and Experimental Therapeutics, 2013 - present  
  • Finalist, LRL President’s Award, Lilly Research Laboratories, 2006  
  • Postdoctoral Scientist Travel Award, ASPET 2006  
  • President, Lilly Research Laboratories Postdoctoral Research Council, 2004 - 2006  
  • Fellow, Neuroscience Training Grant, Indiana University, 2001 - 2003  
  • Member, Sleep Research Society, 2006 - 2010  
  • Member, The Pavlovian Society, 2001 - 2006  
  • Member, Society for Neuroscience, 1999 - present  
  • Member, Research Society on Alcoholism, 1999 - present  
University Teaching Experience:
  • Mentor, Indianapolis Project SEED Summer Research Internship Program, Lilly Research Laboratories, 2013
  • Mentor, Summer Replacement Student Program, Lilly Research Laboratories, 2007-08, 2011-2013
  • Associate instructor of record, Methods of Experimental Psychology; Indiana Univ, spring semester, 2000
  • Assistant instructor, Graduate Course in Advanced Statistics, Introductory Statistics, Introductory Psychology,
  • History and Systems of Psychology, and Neural Bases of Human Behavior
  • Graduate student mentor, MEDIC-B program for undergraduate research; Indiana Univ, academic year 1999
  • Graduate student mentor, McNair Scholars program for undergraduate research; Indiana, academic year 1999
Additional Experience:
  • Steering Committee Co-Chair, Women in Lilly Discovery and Development, Eli Lilly & Co, 2015-present
  • Steering Committee Member, Women in Lilly Discovery and Development, Eli Lilly & Co, 2012-2015
  • Mentor, Various junior scientists in Lilly Research Laboratories, 2012-present
  • Member, Postdoctoral Council Advisory Committee, Eli Lilly and Company, 2009-2013
  • Chair/Organizer, 4 th Biennial LRL Postdoctoral Research Forum, Eli Lilly and Company, 2005
  • Laboratory coordinator, Biobehavioral Alcohol Research Laboratory at Indiana University, 1996-1997
  • Clinical alcoholism research, Biobehavioral Alcohol Research Laboratory at Indiana University, 1995-1997

All content Copyright Women & Hi Tech, BigStockPhoto, or Trusty Applications
Women & Hi Tech is a 501(c)3 charitable organization, and all donations are tax-deductible to the extent allowed by law. Federal ID Number: 35-2113596. 
Women & Hi Tech, 133 West Market Street, #220, Indianapolis, IN 46204
Contact | Personal Data Usage Policy | Site Map